RPHM — Reneo Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $57.82m
- -$45.15m
- 10
- 43
- 14
- 11
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 15.5 | 19.6 | 39.8 | 53.8 | 83.1 |
Operating Profit | -15.5 | -19.6 | -39.8 | -53.8 | -83.1 |
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -12.4 | -19.5 | -39.8 | -52 | -77.4 |
Net Income After Taxes | -12.4 | -19.5 | -39.8 | -52 | -77.4 |
Net Income Before Extraordinary Items | |||||
Net Income | -12.4 | -19.5 | -39.8 | -52 | -77.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -12.4 | -19.5 | -39.8 | -52 | -77.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.514 | -0.804 | -1.63 | -2.12 | -2.52 |
Dividends per Share |